SAN DIEGO — Patients with idiopathic pulmonary fibrosis (IPF) had significant improvements in lung function and reversal of lung fibrosis measures after 12 weeks of therapy with an investigational ...

Promising results from a phase 2 trial of ENV-101, a novel hedgehog inhibitor, showed improvement in lung function and reduction of fibrosis in patients with idiopathic pulmonary fibrosis, said Paul ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted an orphan drug designation to novel hedgehog pathway inhibitor taladegib, also known as ENV-101, ...

Chengdu Sibeibo Pharmaceutical Technology Co. Ltd. has divulged deuterated derivatives of taladegib acting as Hedgehog signaling inhibitors and protein smoothened (SMO) antagonists reported to be ...

A phase II trial of perioperative oral itraconazole for the management of low risk basal cell carcinoma. Cumulative incidence of first adverse event at 3, 6 and 12 months. 3 months [95CI] 6 months ...